<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774747</url>
  </required_header>
  <id_info>
    <org_study_id>D7750090</org_study_id>
    <nct_id>NCT01774747</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety,
      tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in
      subjects with major depressive disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at a single site as a double-blind, placebo-controlled, mulitple
      ascending oral doses evaluation of the safety, tolerability, and pharmacokinetics of DSP-1053
      and its metabolites in healthy subjects with Major depressive disorder after the minimumally
      intolerated dose is reached in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This program was terminated for financial reasons
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To reach minimumally intolerable dose based on stopping criteria</measure>
    <time_frame>14 days</time_frame>
    <description>At least 50% of subjects within a cohort at dose level experience multiple moderate drug related adverse events or one severe drug-related adverse event
one drug related serious adverse event within a cohort at dose level
seizure of any severity or seriousness is observed in a subject who received DSP-1053
Mean plasma DSR_22898 Cmax greater or equal to 32ng/ml for a cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic relationship based on serotonin transporter occupancy of DSP-1053 following multiple oral doses of DSP-1053 in healthy subjects and major depressive disorder subjects</measure>
    <time_frame>14 days</time_frame>
    <description>Measurement of inhibition of active [H]-5HT transport in cells expressing the human serotonin transporter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize exposure of DSP-1053 and its metabolites (AUC, Cmax and Tmax) after multiple ascending dose of DSP-1053</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-1053</intervention_name>
    <description>DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Subjects:

        Be able to understand and willing to sign the Informed Consent Form, and capable of
        providing written authorization for use and disclosure of protected health information per
        requirements of 45 Code of Federal Regulations (CFR) 164.508 (Health Information
        Portability and Accountability Act [HIPAA]).

        Be healthy male or female subjects between 18 and 50 years of age (inclusive). Have a BMI
        18 and 33 kg/m2. Have no clinically relevant abnormal laboratory values at screening and
        Day -1.

        Have no clinically relevant findings from vital sign measurements at screening and
        check-in.

        Have no clinically relevant findings from physical examination at screening and check in.

        Have a negative urine drug of abuse test (cannabinoids, barbiturates, cocaine, opiates,
        benzodiazepines, phencyclidine, and methadone) and negative cotinine test at screening and
        check in.

        Have a negative alcohol breath test at screening and check in. Have a negative Hepatitis B
        surface antigen, Hepatitis C antibody, and human immunodeficiency virus (HIV) antibody
        tests at screening.

        Have normal hepatic function [aspartate transaminase (AST), bilirubin, and alanine
        transaminase (ALT)] and renal function (creatinine clearance greater than 80 mL/min as
        assessed by Cockcroft Gault equation using serum creatinine) at screening and Day 1.

        Be females who are of childbearing potential:

        have a negative serum hCG pregnancy test at screening and Day -1; willing to not breastfeed
        from Day -5 until 90 days after discharge from the study site;

        Be females who are:

        unable to have children (eg, post menopausal, tubal ligation, hysterectomy) OR willing to
        remain abstinent (not engage in sexual intercourse) from check in until 90 days after
        discharge from the study site.

        OR willing to use an effective method of double-barrier birth control (eg, partner using
        condom and female using diaphragm, contraceptive sponge, spermicide, or intrauterine
        device) from check-in until 90 days after discharge from the study site.

        Be males who:

        are sterile or willing to remain sexually abstinent or use an effective method of birth
        control (eg, condom) from check-in until 90 days after discharge from the study site.

        AND agree not to donate sperm during the study and for 90 days after discharge from the
        study site.

        Refrain from strenuous physical activity from 48 hours prior to check-in until discharge
        from the study site.

        Agree to remain housed at the study site for the clinical confinement of study and return
        for any visits required for additional safety or PK assessments.

        Agree to consume study meals per protocol.

        Subjects with MDD:

        In addition to inclusion criteria mentioned above for healthy subjects, the following
        inclusion criteria will be applied to subjects with MDD:

        Have the diagnosis of MDD as defined by the Diagnostic and Statistical Manual of Mental
        Disorders Fourth Edition; Text Revision (DSM IV TR) criteria and confirmed by the Mini
        International Neuropsychiatric Interview (MINI) diagnostic interview. This diagnosis will
        be confirmed by a psychiatrist or psychologist. The diagnosis should be supplemented (when
        possible) by confirmation of chart records or by a discussion with a treating healthcare
        professional or reliable informant. Diagnosis made by a psychologist must be reviewed by a
        psychiatrist.

        The subjects' current major depressive episode must be â‰¥ 4 weeks and &lt; 2 years in duration.

        Are able to wash-out from prior antidepressant therapies by Day -1, are able to forego
        psychotherapy from Day -1 through Day 10, inclusive, and are deemed clinically stable by
        PI's assessment.

        May have a comorbid anxiety disorder such as generalized anxiety disorder (GAD) or social
        phobia but not obsessive compulsive disorder (OCD) as long as the comorbid anxiety disorder
        is not the major source of impairment.

        Have a stable living arrangement for at least 3 months prior to check in and agree to
        return to a similar living arrangement after discharge. This criterion is not meant to
        exclude subjects who have temporarily left a stable living environment. Such subjects
        remain eligible to participate in this study. Chronically homeless subjects should not be
        enrolled. The Medical Monitor should be consulted for individual cases as needed.

        Exclusion Criteria:

        Healthy Subjects

        Significant history or clinical manifestations of any acute or chronic condition that in
        the opinion of the PI, would limit the subject's ability to complete and/or participate in
        the study:

        metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal,
        urological, neurological, or psychiatric disorders; drug hypersensitivity; stomach or
        intestinal surgery or resection that would potentially alter absorption and/or excretion of
        orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be
        allowed at the discretion of the PI); abnormal ECG, which, in the PI's opinion, is
        clinically significant; known or suspected alcohol or substance abuse/ dependence within
        one year prior to check in; movement disorders including tremor; lifetime or family history
        of seizures or a febrile seizure. Poor peripheral venous access. Does not tolerate
        venipuncture. Donation of blood from 28 days prior to screening through study completion,
        inclusive.

        Receipt of blood products within 2 months prior to check in. Any acute or chronic condition
        that, in the opinion of the PI, would limit the subject's ability to complete and/or
        participate in this clinical study.

        Female subjects with menstrual dysfunction. Considered by the PI to be at imminent risk of
        suicide or injury to self, others, or property.

        Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Items 4 or 5 on the CSSRS at screening.

        Subjects who, by history, have smoked or used tobacco products within 60 days from
        screening until study follow up.

        Consumption of food or beverages containing alcohol, grapefruit, or caffeine within 72
        hours prior to check in and until discharge from the study site, unless deemed acceptable
        by the PI.

        Participation in any other investigational study drug trial in which receipt of an
        investigational study drug occurred within 5 half lives or 3 months prior to check-in,
        whichever is longer.

        Taken any drug(s) known to be clinically relevant cytochrome P450 2D6 (CYP2D6), or
        cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 28 days prior to the first DSP
        1053 dose and during the study conduct through follow up.

        Taken any antihistamines within 14 days prior to check-in and during the study. Family
        history of prolonged QT interval (QTc) prolongation. Subjects, who by history, are at any
        risk for bleeding or have abnormal prothrombin values or currently use of anticoagulant
        treatment (such as warfarin) Clinically important folic acid or B12 abnormalities detected
        within 3 months before screening.

        Use of any prescription medications/products within 14 days prior to check in unless deemed
        acceptable by the PI.

        Subjects with MDD

        Except for Exclusion Criterion 18 mentioned above for healthy subjects all exclusion
        criteria will be applied and in addition the following exclusion criteria will be applied
        to subjects with MDD:

        History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating
        disorder, or obsessive compulsive disorder.

        Any current Axis I disorder other than major depressive disorder which is the focus of
        treatment.

        Substance or alcohol abuse in the last 3 months or substance or alcohol dependence in the
        last 12 months.

        Concomitant psychotropic medication, including herbals. Significant risk of violent
        behavior or a significant risk of suicidal behavior based on history or in the PI's
        judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, DSP-1053</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

